Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study by Lauridsen, Camilla et al.
fnagi-08-00030 March 1, 2016 Time: 16:57 # 1
ORIGINAL RESEARCH
published: 01 March 2016
doi: 10.3389/fnagi.2016.00030
Edited by:
Eminy Hsiao-Yuan Lee,
Academia Sinica, Taiwan
Reviewed by:
Kenjiro Ono,
Showa University School of Medicine,
Japan
Yu-Min Kuo,
National Cheng Kung University,
Taiwan
*Correspondence:
Linda R. White
linda.white@ntnu.no
Received: 11 December 2015
Accepted: 08 February 2016
Published: 01 March 2016
Citation:
Lauridsen C, Sando SB, Shabnam A,
Møller I, Berge G, Grøntvedt GR,
Bakken IJ, Salvesen Ø, Bråthen G
and White LR (2016) Cerebrospinal
Fluid Levels of Amyloid Beta 1–43
in Patients with Amnestic Mild
Cognitive Impairment or Early
Alzheimer’s Disease: A 2-Year
Follow-Up Study.
Front. Aging Neurosci. 8:30.
doi: 10.3389/fnagi.2016.00030
Cerebrospinal Fluid Levels of
Amyloid Beta 1–43 in Patients with
Amnestic Mild Cognitive Impairment
or Early Alzheimer’s Disease: A
2-Year Follow-Up Study
Camilla Lauridsen1, Sigrid B. Sando1,2, Adiba Shabnam1, Ina Møller2, Guro Berge1,
Gøril R. Grøntvedt1,2, Inger J. Bakken3, Øyvind Salvesen4, Geir Bråthen1,2 and
Linda R. White1,2*
1 Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway,
2 Department of Neurology, University Hospital of Trondheim, Trondheim, Norway, 3 Norwegian Institute of Public Health,
Oslo, Norway, 4 Unit for Applied Clinical Research, Faculty of Medicine, Norwegian University of Science and Technology,
Trondheim, Norway
Introduction: Biomarkers that will reliably predict the onset of Alzheimer’s disease
(AD) are urgently needed. Although cerebrospinal fluid (CSF) amyloid beta 1–42 (Aβ42),
total tau, and phosphorylated tau can be used to complement the clinical diagnosis
of AD, amnestic mild cognitive impairment (aMCI), the prodromal phase of AD, is
heterogeneous. Biomarkers should be able to determine which patients with aMCI are
at greatest risk of AD. Histological studies and animal models indicate that amyloid beta
1–43 (Aβ43) aggregates early, and may play a role in the pathological process of AD. We
have examined levels of CSF Aβ43 in a 2-year longitudinal study of aMCI and early AD.
Materials and Methods: Cerebrospinal fluid was collected at baseline, and after one
and 2 years from patients with AD (n = 19), and patients with aMCI (n = 42). Of these,
21 progressed to AD during the 2 years of study, whereas 21 did not. Controls (n = 32)
were lumbar punctured at baseline only. CSF analyses of Aβ43, Aβ42, and total tau were
carried out with ELISA.
Results: At baseline, CSF Aβ43, CSF Aβ42 and ratios with total tau could be used to
separate controls from all three patient groups. CSF Aβ43, but not Aβ42, could separate
patients with aMCI who progressed to AD during the 2 years of follow-up, from those
that did not. The CSF total tau/Aβ43 ratio had a slightly but significantly larger area under
the receiver operating characteristic curve when compared to the CSF total tau/Aβ42
ratio. CSF Aβ43 levels, but not Aβ42 levels, decreased from baseline to 2 years in the
AD group.
Discussion and Conclusion: CSF Aβ43 was demonstrated to be significantly reduced
in patients already by the time that aMCI or AD was diagnosed, compared to controls,
and this change must have occurred during the preclinical period. Since our results
suggested that CSF Aβ43 distinguishes between subgroups of patients with aMCI better
than CSF Aβ42, it may prove to be a useful additional biomarker for identifying aMCI
patients at greatest risk of AD.
Keywords: Alzheimer’s disease, amnestic mild cognitive impairment, biomarkers, amyloid beta 1–43, amyloid
beta 1–42, cerebrospinal fluid, diagnostic accuracy
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INTRODUCTION
According to the proposed new diagnostic criteria for Alzheimer’s
disease (AD), early AD can be diagnosed if the prodromal phase
(amnestic mild cognitive impairment, aMCI) is present, and at
least one biomarker is positive, though these biomarkers have yet
to be validated (Albert et al., 2011; McKhann et al., 2011; Dubois
et al., 2014). Biomarkers with high sensitivity and specificity
that reflect the underlying pathology of AD will therefore be
important in identifying patients with aMCI who are most likely
to progress to AD. Such identification will be crucial when
efficient treatment becomes available.
Levels of amyloid beta 1–42 (Aβ42) in cerebrospinal fluid
(CSF) correlate inversely with brain parenchymal Aβ42 load,
as visualized by positron emission tomography (PET) (Fagan
et al., 2006; Tolboom et al., 2009). Additionally, CSF Aβ42
levels have repeatedly been found to be reduced in patients
with MCI and AD, compared to healthy controls (Sunderland
et al., 2003; Hansson et al., 2006). CSF Aβ42 levels are usually
reduced years before clinical symptoms of dementia appear
(Buchhave et al., 2012), and CSF Aβ42 is therefore considered
a candidate biomarker for early AD, alone or in combination
with other CSF biomarkers such as total tau (t-tau) representing
axonal degeneration, or phosphorylated tau representing tau
hyperphosphorylation (Hansson et al., 2006; Tapiola et al., 2009).
The combination of CSF Aβ42 and t-tau has been found to
predict incipient AD with a sensitivity ≥88% and specificity
≥82% (Hansson et al., 2006; Hertze et al., 2010), while CSF Aβ42
alone predicted AD in patients with MCI with a sensitivity of 79%
and specificity of 65% (Mattsson et al., 2009).
Compared to Aβ42, amyloid beta 1–43 (Aβ43) has an
additional threonine at the C-terminal, and is thought to be
more aggregation-prone than Aβ42 (Jarrett et al., 1993; Saito
et al., 2011; Conicella and Fawzi, 2014). Aβ43 was found to
be the first amyloid beta peptide to deposit in mutant amyloid
precursor protein transgenic mice (Zou et al., 2013), and Aβ43
was theorized to provide a ‘seed’ for subsequent Aβ42 deposition
(Conicella and Fawzi, 2014), suggesting that both peptides are
likely to be involved in early plaque formation (Jarrett et al.,
1993; Parvathy et al., 2001). Aβ43 may therefore play a role in
AD pathogenesis despite its low level in brain tissue (Sandebring
et al., 2013), as it has been shown to have equal or even greater
neurotoxicity than Aβ42 in PS1-R278I knock-in mice (Saito et al.,
2011). In a study from human brain tissue, Aβ43 was frequently
found in plaques, and no amyloid peptides longer than Aβ43 were
found (Welander et al., 2009).
To date there are few studies assessing CSF Aβ43 for its
potential as a biomarker in early AD. It has been demonstrated
that CSF Aβ43 was decreased in MCI and AD patients, as well
as being positively correlated to CSF Aβ42 (Kakuda et al., 2012),
despite Aβ43 and Aβ42 being produced by different enzymic
routes (Qi-Takahara et al., 2005). CSF Aβ43 was found to be
slightly inferior to Aβ42 for separating controls from AD patients
(Bruggink et al., 2013).
In the present study, we examined CSF Aβ43 levels at baseline,
and longitudinal levels over a 2-year period, in samples from
patients with aMCI that progressed to AD during this period,
as opposed to those that did not. Levels in patients with AD
from baseline were also studied, and results for healthy control
individuals were available at baseline. Comparisons were made
with CSF levels of Aβ42, including correlations, and ratios with
CSF t-tau.
MATERIALS AND METHODS
Subjects
Patients were recruited through the Department of Neurology,
St. Olav’s Hospital (University Hospital of Trondheim) and
assigned to this study from 2009 onward. Patients were referred
to the clinic by general practitioners, and were diagnosed
by a neurologist (SBS). Patients with early AD (n = 19)
were diagnosed according to the NINCDS–ADRDA criteria
(McKhann et al., 1984), and patients with aMCI (n = 42)
according to the International Working Group on Mild Cognitive
Impairment Criteria (Winblad et al., 2004). Patients were
followed over a 2-year period. During this time, 21 patients
diagnosed with aMCI progressed to AD. This subgroup is
subsequently designated “pMCI” in the results, for convenience.
The remaining 21 patients with aMCI did not progress to AD,
and are similarly designated “sMCI”. All patients were ethnic
Norwegians, with sufficient sight and hearing to complete the
cognitive tests. Exclusion criteria were a present psychiatric or
malignant disease, use of anti-coagulating medication, or high
alcohol consumption.
Thirty-two elderly volunteers were recruited as controls from
societies for retired people in central Norway, or were caregivers
not genetically related to the patient. These control individuals
were also examined by SBS and were healthy for their age without
signs of a neurological disorder. Four had first-degree relatives
with dementia. Controls were examined at baseline and after
2 years, but CSF samples were obtained only at baseline.
The neurological examination performed on both patients and
controls included the Mini Mental State Examination (MMSE)
(Folstein et al., 1975), as well as cerebral MRI at 3T, at baseline,
and after 2 years. Apolipoprotein E (APOE) genotyping was
performed on blood samples from all study participants as
described elsewhere (Berge et al., 2014). Diagnostic assessment
and biomarker analysis were independent of each other. The
demographic data are shown in Table 1.
Sampling of CSF
Cerebrospinal fluid was usually collected early in the morning
with patients lying on their side, and the puncture was at the
L4/L5 or L5/S1 level. The first 2.5 mL CSF was used for routine
clinical investigation. Aliquots of CSF (1 mL) were then collected
directly into 2 mL polypropylene cryovials (Corning) immersed
in ice-water. Samples were not centrifuged unless contaminated
by blood (four samples), and were frozen within 30 min of lumbar
puncture, and stored at−80◦C until analysis.
ELISA Assays
Cerebrospinal fluid was analyzed using ELISA monoplex kits
[Aβ43 (IBL, cat. no. 27710), Aβ42 (Innogenetics, cat. no. 80324),
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TABLE 1 | Demographic data.
aMCI at baseline
Controls sMCI pMCI AD at baseline
Individuals included (n) 32 21 21 19
Gender (% females) 75.0 52.4 57.1 47.4
Age at inclusion (years) 67.3 ± 3.7 65.5 ± 6.4 63.8 ± 4.3 65.6 ± 6.1
Age at onset (years) N/A 63.0 ± 7.1 61.1 ± 4.2 62.4 ± 6.2
Duration of symptoms (years) N/A 2.5 ± 1.5 2.8 ± 1.0 3.2 ± 1.9
% APOE ε4 carriers 31.0 47.6 76.2# 84.2##
Education (years) 13.7 ± 3.2 12.9 ± 3.6 13.2 ± 3.7 12.1 ± 3.8
MMSE score at baseline 29.5 ± 0.7∗ 28.0 ± 1.4∗ 26.6 ± 1.9∗ 22.9 ± 2.9∗
after 1 year N/A 28.1 ± 1.3 24.5 ± 2.5∗∗ 19.4 ± 4.2∗∗, n = 18
after 2 years N/A 28.1 ± 1.3 22.5 ± 2.8∗∗, n = 20 16.9 ± 5.3∗∗, n = 14
Results for continuous variables are given as the mean ± SD. #Significantly different to the control group (p = 0.002). ##Significantly different to the control group
(p < 0.001) and the sMCI group (p = 0.015).∗ Significant difference between all groups at baseline (all pairwise comparisons: p ≤ 0.010).∗∗ Significantly reduced levels
compared to baseline (p ≤ 0.001). AD: Alzheimer’s disease, aMCI: amnestic mild cognitive impairment, sMCI: patients with mild cognitive impairment that did not progress
to AD over 2 years, pMCI: patients with mild cognitive impairment that progressed to AD over 2 years, APOE ε4, apolipoprotein E gene ε4 allele; MMSE, Mini Mental
State Examination; N/A, not applicable.
and total tau protein (Innogenetics, cat. no. 80323)]. Cross-
reactivity for Aβ42 in the Aβ43 ELISA was given as <1%.
Although this would contribute slightly to measurements for
Aβ43, it would be a constant for both control and patient groups.
Aβ43 was reported to have 50x less affinity than Aβ42 for the
antibodies in the Aβ42 kit.
Samples were thawed in ice-water prior to analysis, and
kits were run according to the manufacturers’ instructions. No
samples underwent more than one freeze-thaw cycle, and all
were analyzed undiluted, in duplicate. Both control and patient
samples were included on each plate, and samples from patients
in the three groups were evenly distributed across the plates. For
the Aβ43 assay, an internal control was run on 5 of 6 plates,
yielding an inter-assay CV of 14.4%, and an intra-assay CV
of 5.1%.
Statistical Analysis
Statistical analyses were carried out using SPSS version 22 (IBM),
Stata version 13.1., and R version 2.13.1. For all analyses, p-values
<0.05 were considered statistically significant.
Demographic data and MMSE scores at baseline were assessed
using Pearson’s chi-square test for dichotomous variables, or
one-way ANOVA for continuous variables, followed by the
least-significant difference (LSD) post hoc test for pairwise
comparisons if significant p-values were obtained. Longitudinal
MMSE-scores were analyzed in a mixed linear model. Biomarker
concentrations at baseline, after 1 year and after 2 years, were
log-transformed to the natural logarithm (ln) to approximate to
a normal distribution before comparison of groups by one-way
ANOVA, followed by the LSD post hoc test for pairwise group
comparisons. Pearson’s correlation coefficient (r) for correlations
between biomarkers was also calculated from log-transformed
values.
Receiver operating characteristic (ROC) curves were made
to assess the diagnostic accuracy for individual biomarkers, or
combinations of them, and the area under each ROC curve
(AUC) was calculated.
Youden’s index [(sensitivity + specificity)-1] was determined
to find exploratory cut-offs (not shown) where the sum of
sensitivity and specificity was maximized, for biomarkers or
ratios of biomarkers. Pairwise comparisons of AUC between
Aβ43 and Aβ42, or ratios including these two biomarkers and
total tau protein, were made for pairs of diagnostic groups
(DeLong method). Longitudinal data have been analyzed using
a mixed linear model. To account for repeated measurements,
de-identified patient ID was included as a random effect. The
combination of group and time was included as a fixed effect. All
biomarker concentrations were log-transformed to the natural
logarithm (ln) to approximate to a normal distribution before
analysis in the mixed linear model.
Possible confounding factors included age, gender, and APOE
genotype. Age and gender were found not to be confounding
factors in the present study, and correction for APOE genotype
would have resulted in many small groups, so was not done.
There are results indicating that CSF Aβ42 levels reflect amyloid
deposition in the brain independent of APOE ε4 status (Lautner
et al., 2014), suggesting no need for different cut-offs for CSF
Aβ42 based on APOE ε4 status (Molinuevo et al., 2014).
Ethics
The study was conducted according to the Helsinki Declaration.
Written, informed consent was obtained from all patients or
suitable proxies, and from all control individuals. The biobank
is licensed by the Norwegian Directorate for Health Affairs, and
the research project was approved by the Regional Committee for
Medical Research Ethics, as well as by the Norwegian National
Committees for Medical Research Ethics (approval 2013/150).
RESULTS
Demographic Data
Demographic data are summarized in Table 1. There were no
significant differences in gender distribution between the four
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participant groups (overall p= 0.183), despite a preponderance of
females in the control group. Neither the age at inclusion nor the
duration of education was significantly different between the four
groups. Moreover, no significant difference in the age at onset
of symptoms, or duration of symptoms was found between the
patient groups.
There was a higher prevalence of the APOE ε4 allele in the
pMCI subgroup, and amongst patients with AD, compared to
the control group (both p ≤ 0.002). There was also a higher
prevalence of theAPOE ε4 allele in the AD group compared to the
sMCI subgroup (p = 0.015). The distribution of APOE ε4 alleles
was not significantly different between controls and the sMCI
subgroup, between patients with AD and the pMCI subgroup, or
between sMCI and pMCI subgroups.
At baseline, MMSE-scores varied between all four participant
groups (all pairwise comparisons: p ≤ 0.010). There were
decreases in MMSE-scores from baseline to 2 years in the pMCI
and AD groups (both p< 0.001), but not in the sMCI group.
Biomarker Data at Baseline and
Diagnostic Accuracy
Means and standard deviations of CSF Aβ43, Aβ42, t-tau/Aβ43,
and t-tau/Aβ42 in all groups are shown in Table 2. Means and
error bars in all groups at baseline are shown graphically in
Supplementary Figures S1A–S1D.
Overall, all four analytes or ratios varied between groups at
baseline (all p < 0.001). The CSF Aβ43 level in the control group
was higher than in any patient group (all p< 0.001). The control
group was also significantly different from all patient groups for
the other three analytes or ratios (all p ≤ 0.007). There were
differences between AD and the sMCI subgroup for Aβ43 and
the t-tau/Aβ43 and t-tau/Aβ42 ratios (all p ≤ 0.009), but for
Aβ42 there was only a weak trend (p = 0.086). Aβ43 and the
t-tau/Aβ43 and t-tau/Aβ42 ratios varied between the sMCI and
pMCI subgroups (all p ≤ 0.008), but no difference for Aβ42
levels was found. No significant differences were found between
patients with AD and the pMCI subgroup for any analytes or
ratios.
Cerebrospinal fluid Aβ43 and Aβ42 were correlated in all four
participant groups at baseline (all p ≤ 0.004, r = 0.621–0.853), as
were t-tau/Aβ43 and t-tau/Aβ42 (all p< 0.001, r = 0.903–0.959).
After 1 year, Aβ43 and Aβ42 were still correlated in the sMCI and
pMCI groups (both p ≤ 0.001, r = 0.736–0.912), but not the AD
group. After 2 years, Aβ43 and Aβ42 were correlated in all three
patient groups (all p ≤ 0.019, r = 0.690–0.868). T-tau/Aβ43 and
t-tau/Aβ42 were correlated in all three patient groups both after
1 year and after 2 years (all p< 0.001, r = 0.847–0.969).
Receiver operating characteristic plots (not shown) were
created for baseline levels of biomarkers or ratios thereof,
and statistics were derived for pairwise comparisons of groups
(Table 3). Both CSF Aβ43 and Aβ42 showed similar specificity
in distinguishing control individuals from patients with AD, but
the sensitivity was slightly higher for Aβ43. CSF Aβ43 and Aβ42
were also excellent at separating controls from patients in the
pMCI subgroup, with AUCs over 0.90. Sensitivity and specificity
were all over 90%, except for slightly lower sensitivity of Aβ42.
For separating controls from patients in the sMCI subgroup, all
AUC values were over 0.7, and specificity was high (87–100%),
whereas sensitivity was much lower (53–74%). On the other
hand, the sMCI subgroup was well separated from AD patients
by the t-tau/Aβ43-ratio, with a slightly higher sensitivity than
the corresponding t-tau/Aβ42-ratio. Aβ43 alone also separated
these two groups (AUC 0.73, p = 0.024), while Aβ42 alone
was not significant. The pMCI and AD patient groups were
not separated significantly by any of the biomarkers or ratios
thereof. However, the sMCI and pMCI subgroups were separated
by ratios t-tau/Aβ43 and t-tau/Aβ42 (AUC 0.81 and 0.72,
respectively, p-values 0.001 and 0.018, respectively). T-tau/Aβ43
had higher specificity (90%), whereas t-tau/Aβ42 had higher
sensitivity (85%). When comparing AUC between sMCI and
pMCI subgroups, the t-tau/Aβ43-ratio gave a larger AUC than
the t-tau/Aβ42-ratio (p = 0.040), but for all other comparisons
of Aβ43 and Aβ42, or comparisons of ratios t-tau/Aβ43 and
t-tau/Aβ42 between two and two diagnostic groups, there were
no significant differences in AUC.
Longitudinal Biomarker Levels
Longitudinal biomarker data are given in Table 2. Means and
error bars for CSF Aβ43, Aβ42, t-tau/Aβ43, and t-tau/Aβ42 in
all groups at baseline, after 1 year and after 2 years are shown in
Supplementary Figures S1A–S1D.
After 1 year, group levels varied for CSF Aβ43 and the
t-tau/Aβ43 and t-tau/Aβ42 ratios (all p ≤ 0.003), but not for
CSF Aβ42. For CSF Aβ43, the t-tau/Aβ43 and t-tau/Aβ42 ratios,
there were differences between AD and the sMCI subgroup (all
p ≤ 0.003), and the sMCI and pMCI subgroups (all p ≤ 0.004).
After 2 years, there were variations in group levels for CSF
Aβ43 and the t-tau/Aβ43 and t-tau/Aβ42 ratios (all p ≤ 0.031),
but not for CSF Aβ42. For CSF Aβ43, the t-tau/Aβ43, and
t-tau/Aβ42 ratios, there were differences between AD and the
sMCI subgroup (all p ≤ 0.036), and the sMCI and pMCI
subgroups (all p ≤ 0.016). No significant differences were found
between patients with AD and the pMCI subgroup for any
analytes or ratios at either one or 2 years.
Figures 1A–D show estimated longitudinal biomarker levels
for the mixed linear model, for each participant group. The model
has not been corrected for age at inclusion or gender, as these
factors were not found to significantly affect the model.
CSF Aβ43 showed a decrease from baseline to 1 year after
inclusion in both pMCI (p = 0.023) and AD groups (p = 0.005),
but no significant changes were observed from year one to
year two after inclusion in these two groups. In the AD group,
CSF Aβ43 levels were decreased from baseline to 2 years after
inclusion (p = 0.003), and levels were stable over 2 years in the
sMCI group. For CSF Aβ42, levels were stable over 2 years in all
three patient groups.
For the t-tau/Aβ43-ratio, levels were stable over 2 years in the
AD group. In the sMCI and pMCI groups, the ratio increased
from baseline to 2 years (both p= 0.002). For sMCI, the increase
was significant from year one to year two (p = 0.004), but not
from baseline to 1 year after inclusion. For pMCI, the increase
was significant from baseline to year one (p = 0.010), but not
from year one to year two.
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TABLE 2 | Cerebrospinal fluid (CSF) biomarker data.
aMCI at baseline
Controls n sMCI n pMCI n AD n
Aβ43 (pg/ml) at baseline
after 1 year
after 2 years
44.6 ± 13.1#
N/A
N/A
32 32.0 ± 23.6
31.9 ± 22.1
31.4 ± 22.0
20
20
20
20.0 ± 12.4∗∗
17.8 ± 8.1∗∗
18.7 ± 9.4∗
21
20
20
18.8 ± 7.5∗∗
17.0 ± 6.6∗∗
16.7 ± 7.1∗∗E
18
19
15
Aβ42 (pg/ml) at baseline
after 1 year
after 2 years
1065.5 ± 273.1#
N/A
N/A
25 663.3 ± 348.6
622.4 ± 355.3
631.4 ± 373.5
20
18
18
528.5 ± 178.3
512.3 ± 175.3
529.7 ± 199.3
20
19
19
475.7 ± 169.8
443.2 ± 155.2
476.7 ± 167.1
15
14
14
t-tau/Aβ43 at baseline
after 1 year
after 2 years
7.5 ± 7.6#
N/A
N/A
24 17.3 ± 16.0
17.9 ± 16.9
21.4 ± 22.4 A
19
17
18
47.6 ± 40.0∗∗∗
60.1 ± 53.3∗∗∗
70.9 ± 89.3∗∗∗B
20
18
19
45.1 ± 25.3∗∗∗
49.5 ± 23.9∗∗∗
47.8 ± 37.9∗
14
14
11
t-tau/Aβ42 at baseline
after 1 year
after 2 years
0.35 ± 0.47#
N/A
N/A
23 0.85 ± 1.00
0.91 ± 1.00
1.12 ± 1.47 C
20
18
18
1.70 ± 1.76∗∗
2.04 ± 2.22∗∗
2.61 ± 4.36∗ D
20
19
19
1.88 ± 1.65∗∗∗
1.96 ± 1.62∗∗
1.55 ± 0.72∗
15
14
14
Results are given as the mean ± SD. Significant group differences (analyzed with ANOVA, followed by LSD post hoc test, of log-transformed biomarker data): # Control
group levels at baseline were significantly different from all three patient groups (all p ≤ 0.007). ∗Significantly different from the sMCI group (p < 0.05). ∗∗Significantly
different from the sMCI group (p < 0.01). ∗∗∗Significantly different from the sMCI group (p ≤ 0.001). A graphic representation of the data is given in Supplementary Figures
S1A–S1D. Longitudinal analyses (mixed linear model) of log-transformed biomarker data: increased from baseline to 2 years: A (p = 0.002), B (p = 0.002), C (p < 0.001),
D (p = 0.003). Decreased from baseline to 2 years: E (p = 0.003). AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; sMCI, patients with mild cognitive
impairment that did not progress to AD over 2 years; pMCI, patients with mild cognitive impairment that progressed to AD over 2 years; Aβ43, amyloid beta 1–43; Aβ42,
amyloid beta 1–42; t-tau, total tau; N/A, not applicable.
TABLE 3 | Diagnostic accuracy of CSF biomarkers at baseline.
Controls vs.
AD
Controls vs.
pMCI
Controls vs.
sMCI
sMCI vs.
AD
pMCI vs.
AD
sMCI vs.
pMCI
Aβ43 AUC: 0.97
Sens: 93
Spec: 96
AUC: 0.93
Sens: 90
Spec: 100
AUC: 0.75
Sens: 53
Spec: 100
AUC: 0.73
Sens: 86
Spec: 68
AUC: n.s. AUC: 0.71
Sens: 80
Spec: 68
Aβ42 AUC: 0.96
Sens: 86
Spec: 96
AUC: 0.94
Sens: 85
Spec: 96
AUC: 0.81
Sens: 63
Spec: 92
AUC: n.s. AUC: n.s. AUC: n.s.
t-tau/Aβ43 AUC: 0.94
Sens: 93
Spec: 91
AUC: 0.91
Sens: 90
Spec: 96
AUC: 0.72
Sens: 58
Spec: 91
AUC: 0.83
Sens: 79
Spec: 90
AUC: n.s. AUC: 0.81∗
Sens: 75
Spec: 90
t-tau/Aβ42 AUC: 0.95
Sens: 86
Spec: 96
AUC: 0.91
Sens: 90
Spec: 96
AUC: 0.78
Sens: 74
Spec: 87
AUC: 0.78
Sens: 64
Spec: 90
AUC: n.s. AUC: 0.72∗
Sens: 85
Spec: 63
∗For comparison of sMCI vs. pMCI subgroups, the AUC of the t-tau/Aβ43-ratio is larger than the AUC of the t-tau/Aβ42-ratio (p= 0.040, DeLong method). AD, Alzheimer’s
disease; pMCI, patients with mild cognitive impairment that progressed to AD over 2 years; sMCI, patients with mild cognitive impairment that did not progress to AD
over 2 years; Aβ43, amyloid beta 1–43; Aβ42, amyloid beta 1–42; t-tau, total tau; AUC, area under the ROC curve; Sens, sensitivity (%); Spec, specificity (%); n.s., not
significant.
For the t-tau/Aβ42-ratio, levels were stable over 2 years in the
AD group. In the sMCI and pMCI subgroups, the ratio increased
from baseline to 2 years thereafter (both p ≤ 0.003). For sMCI,
there was an increase from year one to year two (p = 0.015), but
not from baseline to 1 year after inclusion. For pMCI, there was
an increase from baseline to year one (p = 0.018), but not from
year one to year two.
DISCUSSION
Patients with aMCI do not necessarily progress to AD. However,
being able to distinguish individuals that are at greatest risk
of progressing to dementia before brain atrophy becomes
so pronounced that symptoms significantly impair cognitive
function is an important goal for biomarker research. In the
present study, half the patients initially diagnosed with aMCI
progressed to AD during the 2 years of study. This pMCI
subgroup was therefore comparatively homogeneous, given that
patients were all in a prodromal phase, close to the development
of Alzheimer dementia, which probably explains why the pMCI
and AD groups could not be separated by any biomarker or
combination of biomarkers at baseline. The ability to separate out
such patients within the total aMCI group will be urgent once
more effective treatment becomes available to prevent, or at least
slow, disease progression.
At baseline, as well as after one and 2 years, CSF Aβ43 with
or without t-tau in the equation separated patients with aMCI
not progressing to AD within the 2 years of study from patients
that did progress to AD, as well as from those diagnosed with
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FIGURE 1 | (A–D) Longitudinal biomarker levels expressed by a mixed linear model. Estimates of mean log-transformed biomarker levels of (A) CSF Aβ43, (B) CSF
Aβ42, (C) t-tau/Aβ43, and (D) t-tau/Aβ42 over 2 years are shown. © control group (baseline only), l sMCI,  pMCI,  AD. For clarity, the spread of results is not
shown. Means and standard deviations are given in Table 2. All analytes were already significantly changed compared to the control level at baseline. Decreased
Aβ43 levels over 2 years were found in the AD group (p = 0.003). Increased levels over 2 years were found for t-tau/Aβ43 and t-tau/Aβ42 ratios in the sMCI group
(p ≤ 0.002) and in the pMCI group (p ≤ 0.003). Differences between groups at the three time-points are shown in Table 2 and Supplementary Figures S1A–S1D.
Aβ43, amyloid beta 1–43; Aβ42, amyloid beta 1–42; t-tau, total tau; sMCI, patients with mild cognitive impairment that did not progress to Alzheimer’s disease
during the 2 years; pMCI, patients with mild cognitive impairment that progressed to AD during the 2 years of study; AD, Alzheimer’s disease.
AD at baseline. No such significant separation was found for
CSF Aβ42 alone. Therefore, and because t-tau/Aβ43 also seemed
to be at least as good as t-tau/Aβ42 for diagnostic accuracy at
baseline in this study, CSF Aβ43 could be a useful biomarker for
identifying patients with aMCI at greatest risk of AD. However,
even though t-tau/Aβ43 in the present study had a slightly and
significantly larger area under the ROC curve for distinguishing
between the two aMCI subgroups at baseline, t-tau/Aβ42 was
better for identifying patients in an early stage of AD (higher
sensitivity).
To the best of our knowledge, this is the first longitudinal study
of CSF Aβ43 in connection with aMCI and AD. A significant
reduction in the CSF Aβ43 level over the 2 years following
baseline was observed in the AD group, whereas no significant
longitudinal changes in CSF Aβ43 levels were observed in the
sMCI and pMCI groups. The longitudinal changes during the
2 years of study were substantially less in all patient groups
compared to the concentration difference between the control
group and patient groups at baseline. This is an indication
that the reduction of CSF Aβ43 is most pronounced during
the preclinical phase of disease, which may take place slowly
over many years. It is certainly clear that changes in CSF Aβ43
concentration over the 2 years of our study are slow (according
to our data no more than 0.5–1% annually). Since the standard
deviation was relatively small in the AD group, the reduction
was significant. However, this was not the case in the pMCI
or sMCI subgroups where standard deviations were larger, and
indeed there was hardly any change over 2 years in the sMCI
subgroup.
The sMCI subgroup was probably heterogeneous, and
although it contained individuals who have converted to AD
since the end of the study (data not shown), it probably also
contains individuals with control levels that will never convert
to any neurodegenerative disease (Nettiksimmons et al., 2014;
Tifratene et al., 2015). Overall, the annual small change in such
a group is likely to be difficult to detect statistically.
Despite the heterogeneity of the sMCI subgroup, baseline
mean levels of CSF Aβ43 (but not CSF Aβ42) distinguished
significantly between the two aMCI subgroups, even though the
groups were small. Contrary to CSF Aβ43, CSF Aβ42 levels were
stable from baseline to 2 years in all three patient groups, in
agreement with an earlier longitudinal study showing that CSF
Aβ42 levels were stable over 4 years in MCI patients (Mattsson
et al., 2012), and in agreement with results showing fully reduced
CSF Aβ42 levels several years before dementia symptoms appear
(Buchhave et al., 2012).
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CSF Aβ43 and Aβ42 were highly correlated in all four
participant groups at baseline. Aβ43 and Aβ42 are suggested to be
produced from different routes of enzymic cleavage, where three
amino acids are cleaved off the peptides Aβ48 and Aβ49 in two
steps to produce Aβ42 and Aβ43, respectively (Qi-Takahara et al.,
2005). The close correlation of Aβ42 and Aβ43 in the present
study supports a connection between the two synthetic pathways,
as shown earlier (Kakuda et al., 2012).
This is a small study with groups of limited size. In an earlier
study of similar size that compared AD patients with controls,
CSF Aβ43 was found to have similar specificity (97%) but much
lower sensitivity (52%) and lower AUC (0.77) than in the current
study (Bruggink et al., 2013). Such differences between studies
arise easily when comparing small groups, and the present data
should therefore be confirmed in a larger material. However, one
of the main strengths of the present study is that all patients
were diagnosed by a single neurologist, ensuring consistency of
diagnoses between and within groups. Additionally, diagnoses
were confirmed by a second neurologist.
CONCLUSION
Our findings suggest that CSF Aβ43, either alone or in a ratio with
CSF t-tau, may be a useful additional discriminator for patients
with aMCI that will progress to AD within a short period of time.
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